HCAT Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Health Catalyst Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 6.03 USD 7.68%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast HCAT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HCAT is 12.17 USD with a low forecast of 8.08 USD and a high forecast of 16.8 USD.

HCAT Lowest Forecast

Wall Street Target

HCAT Average Forecast

Wall Street Target

HCAT Highest Forecast

Wall Street Target

34% Upside

102% Upside

179% Upside

The latest public price target was made on Jan 26, 2024 by Jack Wallace from Guggenheim , who expects HCAT stock to rise by 132% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Jack Wallace Guggenheim	14 USD Upside 132%	3 months ago Jan 26, 2024	Guggenheim Upgrades Health Catalyst Inc. (HCAT) to Buy StreetInsider

Price Target	14 USD
Upside/Downside	132%

Equasens SA

53% Upside

Carasent ASA

82% Upside

Medlive Technology Co Ltd

29% Upside

Sophia Genetics SA

76% Upside

Equasens SA

53% Upside

Carasent ASA

82% Upside

Medlive Technology Co Ltd

29% Upside

Sophia Genetics SA

76% Upside

Allscripts Healthcare Solutions Inc

87% Upside

Inspire Medical Systems Inc

9% Upside

M3 Inc

43% Upside

4DMedical Ltd

91% Upside

Revenue
Forecast

For the last 5 years the compound annual growth rate for Health Catalyst Inc's revenue is 21%. The projected CAGR for the next 3 years is 11%.

21%

11%

-1%

What are analyst estimates?

Operating Income
Forecast

N/A

N/A

80%

What are analyst estimates?

Net Income
Forecast

N/A

N/A

N/A

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for HCAT is 12.17 USD with a low forecast of 8.08 USD and a high forecast of 16.8 USD.

For the last 5 years the compound annual growth rate for Health Catalyst Inc's revenue is 21%. The projected CAGR for the next 3 years is 11%.

Join more than 132,400+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.